UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 210

Sortiert nach

Passive and active immunization against respiratory syncytial virus for the young and old

Expert review of vaccines, 2017-07, Vol.16 (7), p.737-749

2017

Volltextzugriff (PDF)

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein

mAbs, 2021-01, Vol.13 (1), p.1955812-1955812

2021

Volltextzugriff (PDF)

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2344970-2344970

2024

Volltextzugriff (PDF)

The use of a neonatal mouse model to study respiratory syncytial virus infections

Expert review of anti-infective therapy, 2010-12, Vol.8 (12), p.1371-1380

2010

Volltextzugriff (PDF)

Respiratory syncytial virus vaccines: an update on those in the immediate pipeline

Future microbiology, 2016-10, Vol.11 (11), p.1479-1490

2016

Volltextzugriff (PDF)

Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies

Expert review of vaccines, 2017-04, Vol.16 (4), p.351-360

2017

Volltextzugriff (PDF)

Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles

Human vaccines & immunotherapeutics, 2017-11, Vol.13 (11), p.2594-2605

2017

Volltextzugriff (PDF)

A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus

Human vaccines & immunotherapeutics, 2017-09, Vol.13 (9), p.2092-2097

2017

Volltextzugriff (PDF)

Current concepts and progress in RSV vaccine development

Expert review of vaccines, 2014-03, Vol.13 (3), p.333-344

2014

Volltextzugriff (PDF)

Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform

Human vaccines & immunotherapeutics, 2018-01, Vol.14 (1), p.59-66

2018

Volltextzugriff (PDF)

Evidence for a causal relationship between respiratory syncytial virus infection and asthma

Expert review of anti-infective therapy, 2011-09, Vol.9 (9), p.731-745

2011

Volltextzugriff (PDF)

Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus

Expert review of vaccines, 2008-10, Vol.7 (8), p.1239-1255

2008

Volltextzugriff (PDF)

Respiratory syncytial virus vaccine development

Expert review of vaccines, 2011-10, Vol.10 (10), p.1415-1433

Hurwitz, Julia L

2011

Volltextzugriff (PDF)

The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development

Expert review of vaccines, 2012-12, Vol.11 (12), p.1441-1457

2012

Volltextzugriff (PDF)

Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis

Expert review of vaccines, 2016-02, Vol.15 (2), p.173-187

2016

Volltextzugriff (PDF)

Advances in and the potential of vaccines for respiratory syncytial virus

Expert review of respiratory medicine, 2013-08, Vol.7 (4), p.411-427

2013

Volltextzugriff (PDF)

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo

mAbs, 2018-04, Vol.10 (3), p.453-462

2018

Volltextzugriff (PDF)

Recent advances in the development of subunit-based RSV vaccines

Expert review of vaccines, 2016-01, Vol.15 (1), p.53-68

2016

Volltextzugriff (PDF)

A review of palivizumab and emerging therapies for respiratory syncytial virus

Expert opinion on biological therapy, 2011-11, Vol.11 (11), p.1455-1467

2011

Volltextzugriff (PDF)

Pharmacological management of human respiratory syncytial virus infection

Expert opinion on pharmacotherapy, 2020-12, Vol.21 (18), p.2293-2303

2020

Volltextzugriff (PDF)

Respiratory syncytial virus seasonality and its implications on prevention strategies

Human vaccines & immunotherapeutics, 2018-01, Vol.14 (1), p.234-244

2018

Volltextzugriff (PDF)

Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2341505

2024

Volltextzugriff (PDF)

Respiratory syncytial virus: prospects for new and emerging therapeutics

Expert review of respiratory medicine, 2017-08, Vol.11 (8), p.609-615

2017

Volltextzugriff (PDF)

Progress in the development of virus-like particle vaccines against respiratory viruses

Expert review of vaccines, 2020-01, Vol.19 (1), p.11-24

2020

Volltextzugriff (PDF)

Identifying targets in the hunt for effective respiratory syncytial virus interventions

Expert review of respiratory medicine, 2012-04, Vol.6 (2), p.215-222

2012

Volltextzugriff (PDF)

1 – 25 von 210

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(197)
Mit Volltextzugriff
(133)

Publikationsform

Artikel
(210)

Sprache

Englisch
(210)
Japanisch
(16)

Erscheinungsjahr

n.n

Kollektion

Access via Taylor & Francis
(204)
MEDLINE
(182)
Taylor & Francis Journals Complete
(175)
Journals@Ovid Ovid Full Text
(162)
EZB Electronic Journals Library
(95)
Ingenta
(75)
IngentaConnect Journals
(71)
Publisher website
(41)
Psychology & Behavioral Sciences Collection
(4)

4 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Passive and active immunization against respiratory syncytial virus for the young and old

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

The use of a neonatal mouse model to study respiratory syncytial virus infections

Respiratory syncytial virus vaccines: an update on those in the immediate pipeline

Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies

Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles

A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus

Current concepts and progress in RSV vaccine development

Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform

Evidence for a causal relationship between respiratory syncytial virus infection and asthma

Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus

Respiratory syncytial virus vaccine development

The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development

Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis

Advances in and the potential of vaccines for respiratory syncytial virus

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo

Recent advances in the development of subunit-based RSV vaccines

A review of palivizumab and emerging therapies for respiratory syncytial virus

Pharmacological management of human respiratory syncytial virus infection

Respiratory syncytial virus seasonality and its implications on prevention strategies

Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody

Respiratory syncytial virus: prospects for new and emerging therapeutics

Progress in the development of virus-like particle vaccines against respiratory viruses

Identifying targets in the hunt for effective respiratory syncytial virus interventions

Aktive Filter

Suchergebnisse filtern